Evobrutinib for treating relapsing multiple sclerosis

Evobrutinib is in clinical development for the treatment of relapsing multiple sclerosis (RMS). Multiple sclerosis (MS) is a autoimmune disease that impacts the brain, spinal cord, and optic nerves, which make up the central nervous system (CNS). The cause of MS is not fully clear, but in MS, the immune system attacks the CNS which causes damage to the nerves. RMS is the most common form of MS and it is where you have relapses (symptoms getting worse), which can be followed by recovery (“remitting”). The most common symptoms reported in RMS include episodic tiredness, numbness, vision problems, muscle stiffness, bowel and bladder problems, and problems with cognition (learning and memory or information processing). There is no cure for MS. The overall aim of treatment is to manage symptoms to improve quality of life. Treatment is aimed at reducing the frequency and duration of relapses and at preventing or slowing disability.